REFERENCE
Decision Resources.Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation. Media Release: 15 Jul 2008. Available from: URL: http://www.decisionresources.com
Rights and permissions
About this article
Cite this article
Bapineuzumab may be first disease-modifying AD drug. Pharmacoecon. Outcomes News 558, 10 (2008). https://doi.org/10.2165/00151234-200805580-00030
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805580-00030